Follow The Filings

KRYS Krystal Biotech Inc.

Health Care, filed as KRYSTAL BIOTECH INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.4%
  • $2.8M
  • 1 reduce

In 2026 Q3 Torray Investment Partners trimmed Krystal Biotech.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Reduce 0.37%

Who owns KRYS

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 0.37%, was 0.61% Reduce −31.1% 8,370 $2.8M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by KRYS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All KRYS insider trades
  • None no insider bought on the open market
  • $13.2M sold by 1 insider outside a trading plan
  • $92.1M sold by 5 insiders under 10b5-1 plans
  1. Suma Krishnan President, R&D
    Planned sale
    $9M 25,000 shares at $359.32 1.9% of stake
    Traded Sep 4 Filed Sep 4
    ↗
  2. Krish S Krishnan CEO
    Planned sale
    $9M 25,000 shares at $359.32 1.8% of stake
    Traded Sep 4 Filed Sep 4
    ↗
  3. Dino A Rossi Director
    Sale
    $8.2M 25,000 shares at $329.12 33% of stake
    Traded Aug 14 Filed Aug 14
    ↗
  4. John Charles Thomas EVP, General Counsel
    Planned sale
    $347K 1,000 shares at $347.27 100% of stake
    Traded Jun 25 Filed Jun 26
    ↗
  5. Suma Krishnan President, R&D
    Planned sale
    $7.7M 25,000 shares at $308.11 1.8% of stake
    Traded Jun 4 Filed Jun 5
    ↗
  6. Krish S Krishnan CEO
    Planned sale
    $7.7M 25,000 shares at $308.12 1.7% of stake
    Traded Jun 4 Filed Jun 5
    ↗
  7. John Charles Thomas EVP, General Counsel
    Planned sale
    $194K 642 shares at $302.03 100% of stake
    Traded May 26 Filed May 27
    ↗
  8. Suma Krishnan President, R&D
    Planned sale
    $6.6M 25,000 shares at $263.21 1.8% of stake
    Traded Mar 4 Filed Mar 6
    ↗
  9. Krish S Krishnan CEO
    Planned sale
    $6.6M 25,000 shares at $263.17 1.7% of stake
    Traded Mar 4 Filed Mar 6
    ↗
  10. Kathryn Romano Chief Accounting Officer
    Planned sale
    $201K 750 shares at $267.60 3.2% of stake
    Traded Mar 2 Filed Mar 3
    ↗
  11. Daniel Janney Director
    Planned sale
    $3.3M 11,803 shares at $275.59 14% of stake
    Traded Feb 27 Filed Mar 3
    ↗
  12. Daniel Janney Director
    Planned sale
    $16.1M 60,161 shares at $268.44
    Traded Feb 24–26 Filed Feb 26
    ↗
  13. Dino A Rossi Director
    Sale
    $5M 18,950 shares at $261.41 19% of stake
    Traded Feb 19 Filed Feb 23
    ↗
  14. Kathryn Romano Chief Accounting Officer
    Planned sale
    $3.4M 12,500 shares at $272.14 39% of stake
    Traded Feb 9 Filed Feb 11
    ↗
  15. Suma Krishnan President, R&D
    Planned sale
    $11M 50,000 shares at $220.15
    Traded Dec 4, 2025 Filed Dec 5, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 16 option exercises, 12 share withholdings for taxes, and 4 gifts.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 9.01 Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
10-K Filing Doc
8-K 2.02 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated about 19 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $50.7M $290.52M $389.13M
Net income $10.93M $89.16M $204.83M
Net margin * 21.6% 30.7% 52.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.588B $0.742B $1.02B
Total non-current assets * $230.45M $313.79M $309.19M
Total assets $0.818B $1.06B $1.33B
Total current liabilities $33.09M $102M $102.94M
Total non-current liabilities * $6.62M $7.46M $11.29M
Total equity $0.779B $0.946B $1.22B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$88.8M $123.42M $200.86M
Cash from investing $82.64M -$163.44M -$58.42M
Cash from financing $202.75M $27.01M $8.7M
Net change in cash $196.43M -$13.46M $151.44M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.